Evogene Schedules Second Quarter 2025 Financial Results Release
Evogene (NASDAQ: EVGN), a computational biology company focused on life-science product discovery and development, has scheduled its Q2 2025 financial results release for Tuesday, August 19, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (NASDAQ: EVGN), a computational biology company focused on life-science product discovery and development, has scheduled its Q2 2025 financial results release for Tuesday, August 19, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time).
Interested participants must register in advance through the company's dedicated conference link. A recording of the conference will be made available on Evogene's website following the event.
Details
News Market Reaction – EVGN
The recorded move for EVGN in the trading session of this news was -2.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Zoom conference call scheduled for August 19, 2025, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its subsidiaries, including:
- Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.
For more information, please visit: www.evogene.com.
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-second-quarter-2025-financial-results-release-302515858.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.